ホーム>>Signaling Pathways>> Proteases>> Drug Metabolite>>Olmesartan-d6

Olmesartan-d6

カタログ番号GC49677

オルメサルタンの定量化のための内部標準

Products are for research use only. Not for human use. We do not sell to patients.

Olmesartan-d6 化学構造

Cas No.: 1185144-74-4

サイズ 価格 在庫数 個数
1 mg
$245.00
在庫あり
5 mg
$1,099.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Olmesartan-d6 is intended for use as an internal standard for the quantification of olmesartan by GC- or LC-MS. Olmesartan is a non-peptide angiotensin II receptor 1 (AT1) antagonist (IC50 = 0.0077 µM for the bovine adrenal cortex receptor) and an active metabolite of olmesartan medoxomil .1 It is formed from olmesartan medoxomil by paraoxonase 1 (PON1) in human plasma.2 Olmesartan is selective for AT1 over AT2 (IC50 = >100 µM for the bovine cerebellar receptor). It reduces contraction of isolated guinea pig aorta induced by angiotensin II but not phenylephrine or potassium chloride. Olmesartan (0.01 and 0.03 mg/kg, i.v.) reduces the angiotensin II-induced pressor response in conscious normotensive rats.

1.Mizuno, M., Sada, T., Ikeda, M., et al.Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonistEur. J. Pharmacol.285(2)181-188(1995) 2.Ishizuka, T., Fujimori, I., Nishida, A., et al.Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: Molecular identification and contribution to plasma metabolismDrug Metab. Dispos.40(2)374-380(2012)

レビュー

Review for Olmesartan-d6

Average Rating: 5 ★★★★★ (Based on Reviews and 3 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Olmesartan-d6

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.